Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2025-12-02 Regulatory Filings
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
公司基本資料
Regulatory Filings Classification · 95% confidence The document is a company profile or basic company information disclosure from a public information observation station, containing details such as company name, address, chairman, general manager, contact information, business scope, capital, stock information, accounting firm, and other corporate data. It does not contain financial statements, management discussion, or any report content. The document length is 2755 characters, which is relatively short and appears to be a regulatory disclosure of company basic information rather than a financial report or announcement of a report. There is no indication of an annual report, interim report, earnings release, or any other specific filing type. It is a general regulatory filing providing company information to the public and regulators.
2025-12-02 Chinese
114年第3季海外子公司投資
Interim / Quarterly Report Classification · 90% confidence The document contains financial data related to investment in overseas subsidiaries, including investment amounts, shareholding percentages, and recognized investment gains or losses for the current period. It references specific accounting standards and provides detailed financial figures. The document length is short (653 characters) but contains substantive financial data, not merely an announcement or certification. It is a financial report for a specific period (3rd quarter of year 114 in the local calendar), indicating it is an interim or quarterly report rather than a full annual report or other types. Therefore, the document best fits the category of an Interim / Quarterly Report (IR). 9M 2025
2025-11-13 Chinese
公告本公司國內第二次無擔保轉換公司債114年第3季轉換 普通股之發行新股基準日
Share Issue/Capital Change Classification · 100% confidence The document is a public announcement from a listed company (1786 科妍) regarding the issuance of new shares due to the conversion of domestic unsecured convertible bonds in the third quarter of the year 114 (Taiwan calendar). It details the board resolution date, the amount and number of shares issued, and other specifics about the capital increase. This is a clear announcement about a capital change event, specifically the issuance of new shares following bond conversion. The document is short (958 characters) and focuses on the capital issuance details rather than financial results or reports. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-11-13 Chinese
公告本公司董事會通過114年第三季合併財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1786 科妍) reporting the board's approval of the consolidated financial report for the third quarter of the fiscal year 114 (covering 114/01/01 to 114/09/30). It includes cumulative financial figures such as revenue, gross profit, operating profit, net profit, earnings per share, total assets, liabilities, and equity as of the period end. The document is short (899 characters) and primarily serves as a formal announcement of the board's approval of the quarterly financial report rather than the full detailed report itself. It does not contain detailed financial statements or substantive analysis but summarizes key financial data. Therefore, it fits best as an Interim / Quarterly Report (IR) since it reports quarterly financial results with actual financial data, not merely an announcement of report publication or a certification. The presence of specific financial figures and the reporting period confirms it is a quarterly financial report. 9M 2025
2025-11-13 Chinese
114年第3季大陸投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment information related to investments in mainland China by a Taiwanese listed company. It includes details such as invested capital, investment methods, cumulative investment amounts, and investment income recognized for the period. The document is relatively short (1290 characters) and appears to be a regulatory disclosure of investment details rather than a full financial report or announcement. There is no indication of it being an annual or interim report, earnings release, or management discussion. It also does not fit into categories like board changes, legal proceedings, or capital changes. Given the nature of the data and the context, this is best classified as a Regulatory Filing (RNS), which serves as a general category for regulatory disclosures that do not fit other specific categories.
2025-11-13 Chinese
114年第3季財務報告書 — 202504_1786_AI3.pdf
Annual Report Classification · 95% confidence The document is titled as an individual financial report and auditor's report for fiscal years 114 and 113 (likely corresponding to 2025 and 2024 in the Gregorian calendar). It contains detailed financial statements including balance sheets, income statements, cash flow statements, notes on accounting policies, and auditor's report. The length is substantial (15,000 characters) and it includes comprehensive financial data and analysis, not just an announcement or certification. This matches the definition of an Annual Report (10-K) or a full financial report. Given the presence of the auditor's report and detailed financial statements, it is best classified as an Annual Report (10-K). FY 2025
2025-11-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.